Jilin Aodong (000623.SZ): Net profit of 144 million yuan in the first quarter decreased by 70.43% year on year
Gelonghui, April 29丨Jilin Aodong (000623.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 861 million yuan, up 9.35% year on year; net profit attributable to shareholders of listed companies was 144 million yuan, down 70.43% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 278 million yuan, down 37.51% year on year; basic earnings per share were 0.1277 yuan.
Jilin Aodong Pharmaceutical Group's (SZSE:000623) Problems Go Beyond Poor Profit
Jilin Aodong Pharmaceutical Group Co., Ltd.'s (SZSE:000623) stock wasn't much affected by its recent lackluster earnings numbers. We did some digging, and we believe that investors are missing some w
While Shareholders of Jilin Aodong Pharmaceutical Group (SZSE:000623) Are in the Red Over the Last Five Years, Underlying Earnings Have Actually Grown
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But the main game is to find enough winners to more than offset the lo
Aodong Medicine's 2023 Profit Declines 18%; Revenue Up 20%
Aodong Medicine Industry Group's (SHE:000623) attributable profit fell 18% to 1.46 billion yuan in 2023 from 1.78 billion yuan in 2022, according to a Wednesday filing with the Shenzhen Stock Exchange
Jilin Aodong (000623.SZ): Net profit in 2023 fell 18.02% year-on-year, and plans to distribute 6 yuan for 10 shares
Gelonghui, April 16 | Jilin Aodong (000623.SZ) released its 2023 annual report. Operating revenue was 3.449 billion yuan, up 20.25% year on year, net profit was 1.46 billion yuan, down 18.02% year on year, after deducting non-net profit of 1,313 billion yuan, down 15.63% year on year, with basic earnings per share of 1.2971 yuan. A cash dividend of 6 yuan is distributed to all shareholders for every 10 shares.
Aodong, Jilin (000623.SZ): Produces and sells more than 200 kinds of health products such as functional health foods and dietary nutritional supplements
Gelonghui, March 27丨Jilin Aodong (000623.SZ) said on the investor interactive platform that the company produces and sells more than 200 kinds of health products such as health functional foods and dietary nutritional supplements, including ginseng mushrooms, fermented plant enzymes, immunity enhancement, eye fatigue relief, bone health, fat loss meal replacement, intestinal probiotics, vitamins and minerals.
Aodong, Jilin (000623.SZ): Produces and sells a variety of drugs in the field of proprietary Chinese medicines for kidney supplementation, mainly kidney strengthening pills used for kidney deficiency, poor qi and blood
Gelonghui, March 21丨Jilin Aodong (000623.SZ) said on the investor interactive platform that the company produces and sells a variety of drugs in the field of proprietary Chinese medicines for kidney supplementation, mainly kidney strengthening pills for kidney deficiency and poor qi and blood pressure. Tiange Kidney Supplement is suitable for nephropathy, symptoms such as fatigue, chills, cold legs, and pain in the lower back and knees. Yihechun capsules are used for various symptoms caused by renal impairment. Deer antler takes oral liquid to warm the kidneys, nourish blood, and strengthen bone marrow. It is used for stomach chills and weakness, blood deficiency and dizziness, lower back and knee weakness, and cold and blood loss. Deer Whip Rejuvenation Capsules are used for kidney weakness, insomnia, and amnesia. Five plus blood serum oral solution is used for lower back due to renal impairment
Jilin Aodong (000623.SZ) develops, produces and sells a variety of drugs in the fields of cancer, kidney disease, diabetes, cardiovascular and cerebrovascular diseases
Gelonghui, March 20 | Jilin Aodong (000623.SZ) said on the investor interactive platform that the company is developing, producing and selling a number of drugs in the fields of cancer, nephropathy, diabetes, cardiovascular and cerebrovascular diseases. Among them, injectable ribonucleic acid II is suitable for adjuvant treatment of pancreatic cancer, liver cancer, stomach cancer, lung cancer, breast cancer, soft tissue sarcoma and other cancers, and has a good effect on adjuvant treatment of hepatitis B. This product can also be used for other diseases caused by low immune function. Injectable Pingyangmycin hydrochloride treats head and neck scale cancers such as lip cancer, tongue cancer, gum cancer, and nasopharyngeal cancer. It can also be used to treat skin cancer, breast cancer,
Aodong, Jilin (000623.SZ): Proposed establishment of subsidiary Aodong Anhui Company
Gelonghui, March 18 | Jilin Aodong (000623.SZ) announced that the company held the 8th meeting of the 11th board of directors and the 7th meeting of the 11th board of supervisors to review and pass the “Bill on Foreign Investment” on March 18, 2024. According to the company's development strategy plan, the company and its holding subsidiary Jilin Aodong Yanbian Pharmaceutical Co., Ltd. (“Yanbian Pharmaceutical”) jointly invested 300 million yuan to establish a subsidiary, Aodong Pharmaceutical (Anhui) Co., Ltd. (tentative name, subject to local industrial and commercial approval, referred to as “Aodong Anhui Company”) Investment 3 million yuan, accounting for Aodong and Anhui
Here's Why Jilin Aodong Pharmaceutical Group (SZSE:000623) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi
Aodong, Jilin (000623.SZ): The production and sale of injectable ribonucleic acid II is an immunomodulator
Gelonghui March 12 | Jilin Aodong (000623.SZ) said on the investor interactive platform that injectable ribonucleic acid II produced and sold by the company is an immunomodulator. It is suitable for adjuvant treatment of pancreatic cancer, liver cancer, stomach cancer, lung cancer, breast cancer, soft tissue sarcoma and other cancers, and has a good effect on adjuvant treatment of hepatitis B. This product can also be used for other diseases caused by low immune function. The company's chemicals include chemical injections, general chemical drugs, and chemical raw materials. Currently, the company's chemicals mainly include injectable ribonucleic acid II, injectable Pingyangmycin hydrochloride, and artificial beeswax metronidazole
Aodong, Jilin (000623.SZ): The holding subsidiary obtained a registration certificate for the marketing of traditional Chinese medicine formula granules
Gelonghui, March 8, 丨 Jilin Aodong (000623.SZ) announced that the holding subsidiary Jilin Aodong Yanbian Pharmaceutical Co., Ltd. has obtained 11 “Registration Certificates for the Marketing of Traditional Chinese Medicine Formula Granules”.
Jilin Aodong (000623.SZ) issued 2 billion yuan medium-term notes and was accepted for registration
Jilin Aodong (000623.SZ) issued an announcement. The company recently received an announcement from the China Interbank Market Dealers Association...
Aodong, Jilin (000623.SZ): Relying on the advantages of the pharmaceutical industry, the company produces a series of products based on the resources of the Changbaishan region, such as proprietary Chinese medicines, Chinese herbal medicines, health produ
Gelonghui, March 7 | Jilin Aodong (000623.SZ) said on the investor interactive platform that the company insists on integrating party building work into all aspects of production and operation, pushes party members and employees to compete for pioneers and set an example, and turns the Party branch into a strong grassroots battlebastion. The company actively promotes the main theme, spreads positive energy, and combines its own industrial advantages to actively fulfill its social responsibilities. Relying on the advantages of the pharmaceutical industry, the company mobilized the enthusiasm of local farmers to actively participate in the cultivation and cultivation of Chinese herbal medicines through the production of a series of products, such as proprietary Chinese medicines, Chinese herbal medicine tablets, and health products, mainly from the Changbaishan region, and supported and encouraged plum
Aodong, Jilin (000623.SZ): Currently, there are 616 drug production approval numbers. A total of 206 products have been included in the national medical insurance catalogue, and a total of 91 products have entered the national essential drug catalogue
Gelonghui, March 7 | Jilin Aodong (000623.SZ) said on the investor interactive platform that the company currently has 616 drug production approval numbers, a total of 206 products have been included in the national medical insurance catalogue, and a total of 91 products have entered the national essential drugs catalogue. The pediatric drug catalogue categories include Pediatric Chai Gui Antipyretic Oral Liquid and Sports Digestive Oral Liquid. As a national exclusive patented product (Patent No.: ZL200410010761.1), Pediatric Chai Gui Antipyretic Oral Liquid has developed into a core variety after years of cultivation. The company insists on continuing to deepen the field of pediatrics and increase investment in scientific research and academics
Aodong, Jilin (000623.SZ): Pibacilli capsules and pibasilil APIs approved
Zhitong Finance App News, Jilin Aodong (000623.SZ) issued an announcement. Recently, the company's holding subsidiary, Jilin Aodong Taonan Pharmaceutical Co., Ltd. (“Taonan Pharmaceutical”), received the specifications of pibesilil capsules issued by the State Drug Administration: 100 mg, 75 mg, 125 mg, three “Drug Registration Certificates” and pibesilil's “Notice of Approval of the Marketing Application for Chemical Ingredients”. The approval of pibesilil capsules and pibesilil APIs has improved the company's product structure, further enriched the company's range of APIs and capsule formulations, enhanced the company's core competitiveness, and further strengthened the company
Aodong, Jilin (000623.SZ): Taonan Pharmaceutical obtained a drug registration certificate and a notice of approval for the marketing application of chemical raw materials
Gelonghui, March 1, 丨 Jilin Aodong (000623.SZ) announced that recently, Jilin Aodong Taonan Pharmaceutical Co., Ltd. (“Taonan Pharmaceutical”), a holding subsidiary of Jilin Aodong Pharmaceutical Group Co., Ltd., received the specifications of pibesilide capsules issued by the State Drug Administration: 100 mg, 75 mg, 125 mg, and the “Notice of Approval of Application for the Marketing of Chemical Ingredients”.
Aodong, Jilin (000623.SZ): The company has a variety of drugs used to prevent influenza virus, treat influenza, and reduce fever
Gelonghui, Feb. 27丨Jilin Aodong (000623.SZ) said on the investor interactive platform that the company has a variety of drugs used to prevent the influenza virus, treat influenza, and reduce fever. “Chai Gui Antipyretic Oral Solution for Children” is a traditional Chinese medicine for fever relief. It has the function of relieving sweating and relieving fever. Used for external fever in children. Symptoms: fever, headache, runny nose, thirst, red throat, yellow, dry stools. Currently, “Pediatric Chai Gui Antipyretic Oral Solution” has been recommended for use in multiple clinical guidelines. In clinical applications, it also has specific symptoms such as “high cure rate, low recurrence rate, short treatment cycle, stable and no rebound in fever”
Aodong, Jilin (000623.SZ): CXO and CRO related businesses have not been deployed
Gelonghui, Feb. 26 | Aodong, Jilin (000623.SZ) said on the investor interactive platform that the company is a pharmaceutical manufacturer, mainly engaged in R&D, manufacturing and sales of traditional Chinese medicines and chemicals. Currently, the company's business scope covers proprietary Chinese medicines, traditional Chinese medicine formula granules, Chinese medicine tablets, chemicals, etc., while actively laying out health food, food, breeding, planting and other fields, gradually forming a “pharmaceutical+finance+big health” multi-wheel drive development model. The company has no CXO and CRO related businesses.
Aodong, Jilin (000623.SZ): By the end of 2023, the company had registered 400 varieties of traditional Chinese medicine formula granules
Gelonghui Feb. 21丨Jilin Aodong (000623.SZ) held a roadshow on February 21, 2024 to discuss “How is the filing and collection of Chinese medicine formula granules in the company?” The company replied that by the end of 2023, the company had registered 400 varieties of traditional Chinese medicine formula granules for marketing. Traditional Chinese medicine formula granules are the company's development business. The company has established complete, comprehensive and strict product standards, and achieved quality control throughout the process of formula granules from medicinal materials to finished products. It has shown significant advantages in the supply chain, quality assurance, and service system. The number and production capacity of traditional Chinese medicine formula granules can fully meet the requirements
No Data